After pandemic delay and a South Korean deal, Boston-area biotech raises Series B with sights on IPO

Two years after snaring a $45 million Series A from a couple of top-flight investors, Neurogastrx was finally ready to put its lead molecule into the clinical trials when the world shut down in March 2020.

The small, GI-focused biotech’s plans were, like many that spring, derailed.

“A lot of institutions were not allowing patients into hospitals or testing centers,” CEO Jim O’Mara said. “That delayed us for months.”